Exemestane

Common brands: Aromasin, Afinitor Disperz, Afinitor, Femara, Letrozole

Top reporter: Pharmacia & Upjohn Company Llc

Aromatase Inhibitor [EPC]Kinase Inhibitor [EPC]mTOR Inhibitor Immunosuppressant [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Estrogen Receptor Antagonist [EPC]
21,059
Total Reports
7,243
Serious Reports
2,492
Death Reports
30
Reported Reactions
Death Report Ratio: High (11.83%)

Patient Demographics

Male
217
Female
19,126

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Exemestane.

# Reaction Reports % of Total
1 FATIGUE 2,205
7.0%
2 MALIGNANT NEOPLASM PROGRESSION 1,794
5.7%
3 ARTHRALGIA 1,703
5.4%
4 NAUSEA 1,692
5.4%
5 DIARRHOEA 1,681
5.4%
6 DYSPNOEA 1,391
4.4%
7 PAIN 1,123
3.6%
8 ASTHENIA 1,071
3.4%
9 HEADACHE 1,061
3.4%
10 MALAISE 1,059
3.4%
11 COUGH 1,019
3.2%
12 VOMITING 982
3.1%
13 DISEASE PROGRESSION 967
3.1%
14 DEATH 930
3.0%
15 NEOPLASM PROGRESSION 924
2.9%
16 METASTASES TO BONE 913
2.9%
17 DECREASED APPETITE 883
2.8%
18 DIZZINESS 878
2.8%
19 ALOPECIA 867
2.8%
20 PYREXIA 837
2.7%
21 BREAST CANCER METASTATIC 835
2.7%
22 INSOMNIA 787
2.5%
23 BREAST CANCER 777
2.5%
24 STOMATITIS 777
2.5%
25 METASTASES TO LIVER 749
2.4%
26 WEIGHT DECREASED 735
2.3%
27 PRURITUS 728
2.3%
28 RASH 713
2.3%
29 DRUG INEFFECTIVE 648
2.1%
30 PAIN IN EXTREMITY 648
2.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.